ATE302014T1 - Immunstimulierende bakterienwandfraktionen zur krebsbehandlung - Google Patents

Immunstimulierende bakterienwandfraktionen zur krebsbehandlung

Info

Publication number
ATE302014T1
ATE302014T1 AT00910947T AT00910947T ATE302014T1 AT E302014 T1 ATE302014 T1 AT E302014T1 AT 00910947 T AT00910947 T AT 00910947T AT 00910947 T AT00910947 T AT 00910947T AT E302014 T1 ATE302014 T1 AT E302014T1
Authority
AT
Austria
Prior art keywords
immuno
cancer treatment
wall fractions
bacteria wall
preparing
Prior art date
Application number
AT00910947T
Other languages
English (en)
Inventor
Christine Libon
Nathalie Corvaia
Alain Beck
Jean-Yves Bonnefoy
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pf Medicament filed Critical Pf Medicament
Application granted granted Critical
Publication of ATE302014T1 publication Critical patent/ATE302014T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
AT00910947T 1999-03-15 2000-03-15 Immunstimulierende bakterienwandfraktionen zur krebsbehandlung ATE302014T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9903154A FR2790960B1 (fr) 1999-03-15 1999-03-15 Utilisation de fractions membranaires bacteriennes a activite immunostimulante dans le traitement de cancers, leurs procedes de preparation et les compositions pharmaceutiques les contenant
PCT/FR2000/000623 WO2000054790A1 (fr) 1999-03-15 2000-03-15 Fractions membranaires bacteriennes immunostimulantes dans le traitement de cancers

Publications (1)

Publication Number Publication Date
ATE302014T1 true ATE302014T1 (de) 2005-09-15

Family

ID=9543185

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00910947T ATE302014T1 (de) 1999-03-15 2000-03-15 Immunstimulierende bakterienwandfraktionen zur krebsbehandlung

Country Status (14)

Country Link
US (1) US7033591B1 (de)
EP (1) EP1161250B9 (de)
JP (1) JP2002539170A (de)
CN (1) CN1202127C (de)
AT (1) ATE302014T1 (de)
AU (1) AU776350B2 (de)
BR (1) BR0009052A (de)
CA (1) CA2367211A1 (de)
DE (1) DE60022011T2 (de)
DK (1) DK1161250T3 (de)
ES (1) ES2246831T3 (de)
FR (1) FR2790960B1 (de)
WO (1) WO2000054790A1 (de)
ZA (1) ZA200107368B (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2808445A1 (fr) * 2000-05-04 2001-11-09 Pf Medicament Proteine omp associee a un lysat de cellules tumorales autologues et/ou heterologues
FR2809014A1 (fr) * 2000-05-16 2001-11-23 Pf Medicament Utilisation d'une proteine ompa d'enterobacterie comme agent antimicrobien
GB2370838A (en) 2001-01-06 2002-07-10 Benedikt Timmerman Immunogenic complex
FR2822071B1 (fr) * 2001-03-15 2005-07-01 Pf Medicament Utilisation d'une fraction membranaire de bacteries a gram negatif pour induire la maturation des cellules dendritiques
EP3074003B1 (de) * 2013-11-26 2023-01-11 Zoetis Services LLC Zusammensetzungen zur induktion von immunreaktion
GB201713975D0 (en) * 2017-08-31 2017-10-18 Macrophage Pharma Ltd Medical use
TW202045192A (zh) * 2019-02-22 2020-12-16 美商艾弗洛生物科技股份有限公司 細菌膜製劑
EP4190894A1 (de) 2021-12-03 2023-06-07 CiMaas B.V. Verfahren zur in-vitro-herstellung von reifen dendritischen zellen unter verwendung eines bakteriellen lysats

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2471785A1 (fr) * 1979-12-21 1981-06-26 Fabre Sa Pierre Preparations immunostimulantes a base d'arn ribosomaux et procede de preparation des arn
FR2523154A1 (fr) * 1982-03-09 1983-09-16 Fabre Sa Pierre Procede de preparation de proteoglycanes immunostimulants inducteurs d'interferon, proteoglycanes obtenus et medicaments les contenant
FR2596064B1 (fr) * 1986-03-18 1990-02-02 Pf Medicament Procedes industriels de fabrication de vaccins ribosomaux et vaccins ribosomaux obtenus
EP0268640A4 (de) * 1986-05-07 1989-11-30 Sloan Kettering Inst Cancer Impfstoff zur stimulierung oder erhöhung von antikörpern gegen gm2.
AU7477791A (en) * 1990-03-02 1991-09-18 Joaquin J. Jimenez Method for treating cancer using combination chemotherapy and brm
US5242806A (en) * 1990-05-07 1993-09-07 Baxter Diagnostics Inc. Method for conducting the cytotoxicity assays on tumor cells
US5776898A (en) * 1991-05-14 1998-07-07 Dana-Farber Cancer Institute Method for treating a tumor with a chemotherapeutic agent
US5830686A (en) * 1994-01-13 1998-11-03 Calydon Tissue-specific enhancer active in prostate
FR2726472B1 (fr) * 1994-11-07 1997-01-31 Pf Medicament Proteine porteuse a effet adjuvant, complexe immunogene la contenant, leur procede de preparation, sequence nucleotidique et vaccin
US5633161A (en) * 1995-03-29 1997-05-27 Millennium Pharmaceuticals, Inc. Murine gene fomy030 coding for tumor progression inhibitor
FR2785542B1 (fr) * 1998-11-06 2001-02-09 Pf Medicament UTILISATION D'UNE PROTEINE OmpA D'ENTEROBACTERIE, POUR LE CIBLAGE SPECIFIQUE D'UNE SUBSTANCE BIOLOGIQUEMENT ACTIVE QUI LUI EST ASSOCIEE VERS LES CELLULES PRESENTATRICES D'ANTIGENES TELLES QUE LES CELLULES DENDRITIQUES HUMAINES

Also Published As

Publication number Publication date
FR2790960B1 (fr) 2002-10-31
ZA200107368B (en) 2002-06-26
CN1202127C (zh) 2005-05-18
AU776350B2 (en) 2004-09-02
FR2790960A1 (fr) 2000-09-22
ES2246831T3 (es) 2006-03-01
JP2002539170A (ja) 2002-11-19
DE60022011D1 (de) 2005-09-22
US7033591B1 (en) 2006-04-25
WO2000054790A1 (fr) 2000-09-21
EP1161250B9 (de) 2006-07-05
BR0009052A (pt) 2001-12-26
DK1161250T3 (da) 2005-12-12
EP1161250B1 (de) 2005-08-17
CN1343125A (zh) 2002-04-03
AU3298100A (en) 2000-10-04
DE60022011T2 (de) 2006-06-14
CA2367211A1 (fr) 2000-09-21
EP1161250A1 (de) 2001-12-12

Similar Documents

Publication Publication Date Title
MX2025003080A (es) Conjugados de il-15, y sus usos
WO2004018000A3 (en) Compositions and methods for treating cancer using maytansinoid cd44 antibody immonoconjugates and chemotherapeutic agents
TR200301846T2 (tr) Cripto bloke edici Antikorlar ve bu antikorların kullanımları.
ATE439137T1 (de) Behandlung von hämatologischen störungen
IL184617A0 (en) Dr5 antibodies and uses thereof
WO2003030934A3 (en) Cpg formulations and related methods
BRPI0207961A8 (pt) Uso de análogos de epotilona e capecitabina para fabricar medicamento para tratar tumores cancerosos sólidos e kit compreendendo os referidos compostos.
HUP0400231A3 (en) Methods and pharmaceutical compositions for immune deception, particularly useful in the treatment of cancer
IL146125A0 (en) Novel quinones as disease therapies
HRPK20041072B3 (hr) Primjena docetaxela/doxorubicina/ciklofosfamida uadjuvantnoj terapiji karcinoma dojke i jajnika
TW200600091A (en) Sulfonylethyl phosphorodiamidates
BR9510490B1 (pt) composição farmacêutica combinada de dois componentes estruturada para uso em um hospedeiro.
ATE302014T1 (de) Immunstimulierende bakterienwandfraktionen zur krebsbehandlung
MXPA05009480A (es) Metodos y composiciones para la sintesis enzimatica de gangliosidos.
EP2623601A3 (de) Stabilisierte Aptamere für einen aus Plättchen gewonnenen Wachstumsfaktor und ihre Verwendung als Krebstherapiemittel
WO2002066492A3 (fr) Anticorps specifique de l'adrenomedulline humaine, composition pharmaceutique le contenant, ses applications therapeutiques.
ATE346602T1 (de) Bakterienwandfraktionen mit adjuvansaktivität
IL148336A0 (en) Medicaments that contain xenogenic oligo-or/and polyribonucleotides
GEP20074097B (en) Use of specific dose of fondaparinux sodium for the treatment of acs
AU2001256440A1 (en) Medicines for treating tumoral pathologies containing the ro5-4864 compound and an apoptosis-inducing agent
MD2053C2 (ro) Remediu cu acţiune interferonogenă
IL159469A0 (en) Xenogenic oligo-or/and polyribonucleotides as agents for the treatment of malignant tumours
EP1417968A3 (de) Antitumor Zusammensetzungen enthaltend Propolis und Resveratrol
UA88468C2 (ru) Сульфонилэтилфосфородиамидаты, предназначенные для применения при лечении рака
Chevailler Hommage à Nils-Olivier Olsson

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1161250

Country of ref document: EP

REN Ceased due to non-payment of the annual fee